Grimes & Company, Inc. Adma Biologics, Inc. Transaction History
Grimes & Company, Inc.
- $3.31 Billion
- Q2 2024
A detailed history of Grimes & Company, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 39,987 shares of ADMA stock, worth $723,364. This represents 0.01% of its overall portfolio holdings.
Number of Shares
39,987
Previous 45,267
11.66%
Holding current value
$723,364
Previous $298,000
50.0%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ADMA
# of Institutions
265Shares Held
178MCall Options Held
535KPut Options Held
21.2K-
Black Rock Inc. New York, NY18.6MShares$337 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$263 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA13.2MShares$238 Million0.03% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL8.93MShares$161 Million0.03% of portfolio
-
State Street Corp Boston, MA8.06MShares$146 Million0.0% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.55B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...